Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 11/20 | 0.65 |
| ▸ | CNR2 | P34972 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 5/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5058767 | 0.93 | CNR1 (0.72) | CNR1CNR2MAPTTP53SMN1; SMN2 | |
| SCHEMBL13808050 | 0.89 | CNR1 (0.51) | CNR1CNR2MAPTTP53SMN1; SMN2 | |
| SCHEMBL13808250 | 0.88 | CNR1 (0.83) | CNR1CNR2MAPTTP53SMN1; SMN2 | |
| SCHEMBL5064679 | 0.88 | CNR1 (0.57) | CNR1CNR2MAPTTP53SMN1; SMN2 | |
| SCHEMBL13808167 | 0.88 | CNR1 (0.57) | CNR1CNR2MAPTTP53SMN1; SMN2 | |
| SCHEMBL5064659 | 0.86 | CNR1 (0.79) | CNR1CNR2MAPTTP53SMN1; SMN2 | |
| SCHEMBL13808249 | 0.86 | CNR1 (0.74) | CNR1CNR2TP53SMN1; SMN2 | |
| SCHEMBL14205913 | 0.86 | CNR1 (0.79) | CNR1CNR2MAPTTP53SMN1; SMN2 | |
| SCHEMBL5577088 | 0.84 | CNR1 (0.59) | CNR1CNR2MAPTTP53SMN1; SMN2 | |
| SCHEMBL5064748 | 0.82 | CNR1 (0.79) | CNR1CNR2MAPTTP53SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009075691-A1 | CB-1 MODULATING COMPOUNDS AND THEIR USE | ACADIA PHARMACEUTICALS INC. (US) | 2009-06-18 | — | — | WO | disclosed |
| WO-2008118141-A2 | USE OF CANNABINOID MODULATING COMPOUNDS IN COMBINATION WITH OTHER THERAPEUTIC COMPOUNDS FOR ADJUNCTIVE THERAPY | ACADIA PHARMACEUTICALS INC. (US) | 2008-10-02 | — | — | WO | disclosed |
| US-20080090805-A1 | CB-1 MODULATING COMPOUNDS AND THEIR USE | ACADIA PHARMACEUTICALS INC. (US) | 2008-04-17 | — | — | US | disclosed |
| US-20080090805-A1 | CB-1 MODULATING COMPOUNDS AND THEIR USE | ACADIA PHARMACEUTICALS INC. (US) | 2008-04-17 | — | — | US | disclosed |
| US-20080090805-A1 | CB-1 MODULATING COMPOUNDS AND THEIR USE | ACADIA PHARMACEUTICALS INC. (US) | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090805-A1 | CB-1 MODULATING COMPOUNDS AND THEIR USE | CNR1, CNR2, FAAH | CNR1 1/4885CNR2 2/4885MAPT 3344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.